Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
There’s ‘super flu,’ COVID, RSV. Is it going around in SoCal? - 2Unsold Rams May Be Less expensive Than You Suspect
- 3South Carolina measles outbreak grows by nearly 100, spreads to North Carolina and Ohio
- 4Public mistrust linked to drop in deceased donor organ donations and kidney transplants
- 5Steven Spielberg's 'Disclosure Day' trailer drops: What we know about the alien movie
- What we know about Jonathan Ross, the ICE agent who shot and killed Renee Nicole Good in Minneapolis
- As world leaders enter climate talks, people in poverty have the most at stake
- Medical team successfully delivers baby and removes massive tumor
- College students are now slightly less likely to experience severe depression, research shows – but the mental health crisis is far from over
- Best Amusement Park in Europe: Where Do You Very much want to Visit?
- This Week In Space podcast: Episode 187 — An Inspired Enterprise
- Winter solstice 2025 marks the shortest day of the year in the Northern Hemisphere today
- Congolese rape survivors search in vain for medicine after USAID cuts
- Director Emerald Fennell explains why "Wuthering Heights" has quotation marks around the title
